Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Meta Shifts Focus: Major Metaverse Budget Cuts Signal AI Pivot

Dieter Jaworski by Dieter Jaworski
December 9, 2025
in AI & Quantum Computing, Earnings, Gaming & Metaverse, Tech & Software, Turnaround
0
Meta Stock
0
SHARES
25
VIEWS
Share on FacebookShare on Twitter

In a significant strategic reversal, Meta Platforms Inc. is dramatically scaling back its investment in the metaverse. The company is redirecting approximately 30% of its budget for this initiative toward artificial intelligence and its highly profitable core advertising operations. This move by CEO Mark Zuckerberg represents a decisive pullback from what has been a costly, multi-year experiment.

Core Advertising Business Demonstrates Robust Health

The rationale for this strategic shift becomes clear when examining the performance of Meta’s foundational businesses. The Family of Apps segment—encompassing Facebook, Instagram, WhatsApp, and Messenger—remains a financial powerhouse. For the first nine months of 2025, this division generated $139.8 billion in revenue, delivering an operating profit of $71.7 billion.

Excluding the substantial losses from its Reality Labs unit, the operating margin for Meta’s advertising business stands at an impressive 51.3%. Even when consolidated with the metaverse division’s results, the company maintains a robust overall operating margin of 43.3%, a level of profitability few global technology firms can match.

Reality Labs: Billions in Cumulative Losses

The financial burden of the metaverse venture is staggering. Meta’s Reality Labs division has accumulated losses totaling $71 billion since 2021. The unit’s performance has consistently deteriorated year-over-year, with annual losses deepening:

  • 2021: $10.19 billion loss
  • 2022: $13.72 billion loss
  • 2023: $16.12 billion loss
  • 2024: $17.73 billion loss

For the initial three quarters of 2025 alone, the division reported a loss of $13.27 billion against meager revenue of just $1.3 billion. As a consequence of the budget reductions, projects including the Horizon Worlds metaverse platform and the Quest virtual reality hardware line will be affected. Initial layoffs within these teams are anticipated for January 2026.

Should investors sell immediately? Or is it worth buying Meta?

EU Agreement Provides Regulatory Clarity

Concurrently, Meta has reached an agreement with the European Commission concerning its advertising practices. Starting in January 2026, users in Europe will be given a choice regarding how their personal data is utilized for targeted advertising. This settlement resolves a dispute linked to a potential €200 million penalty under the EU’s Digital Markets Act (DMA), providing the company with clearer operational guidelines in a key market.

Artificial Intelligence Emerges as Primary Investment Focus

The reallocation of resources underscores Meta’s conviction that artificial intelligence offers more immediate promise than virtual reality. Freed-up capital is being channeled into several AI-focused areas: the construction of proprietary data centers, advancement of the Llama large language model, enhancement of the Meta AI assistant, and the algorithmic optimization of content and advertising delivery.

Despite this strategic pivot, Meta’s overall capital expenditure remains substantial. The company has guided for 2025 expenses in the range of $70 to $72 billion, with management signaling even higher investment levels for the 2026 fiscal year.

Investors will gain further insight into the permanence of this strategic overhaul and the specific restructuring plans for Reality Labs when Meta releases its next quarterly earnings report on January 28, 2026.

Ad

Meta Stock: Buy or Sell?! New Meta Analysis from February 7 delivers the answer:

The latest Meta figures speak for themselves: Urgent action needed for Meta investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Meta: Buy or sell? Read more here...

Tags: META
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Golden Entertainment Stock
Gaming & Metaverse

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Next Post
Amazon Stock

Amazon's Strategic Pivot in AI Chip Development

Tilray Stock

Tilray Shares Face Renewed Pressure as Analyst Slashes Price Target

Coinbase Stock

Coinbase Charts a Return to the Indian Market Amid Stock Volatility

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com